MDM2 and Merkel cell skin cancer: MDM2/4 inhibitors show reduced growth in mouse MCC models.KRT-232 or Navtemadlin, an oral inhibitor of MDM2, is in clinical trial for immunotherapy-naïve or in combination with Avelumab for checkpoint inhibitor-refractory MCC (NCT03787602).